Biologics. 2008 Jun;2(2):285-96. doi: 10.2147/btt.s1954.
Biologics : targets & therapy
Paul N Knoebl
PMID: 19707361 PMCID: PMC2721356 DOI: 10.2147/btt.s1954
The protein C pathway has an important function in regulating and modulating blood coagulation and ensuring patency of the microcirculation. Protein C deficiency leads to macro- and microvascular thrombosis. Congenital severe protein C deficiency is a life-threatening state with neonatal purpura fulminans and pronounced coagulopathy. Patients with heterozygous protein C deficiency have an increased risk for thromboembolic events or experience coumarin-induced skin necrosis during initiation of coumarin therapy. Replacement with protein C concentrates is an established therapy of congenital protein C deficiency, resulting in rapid resolving of coagulopathy and thrombosis without reasonable side effects. This article summarizes the current knowledge on protein C replacement therapy in congenital protein C deficiency.
Keywords: coagulopathy; deficiency; protein C; purpura fulminans; replacement therapy